Ophthalmic Drug Dispensers Being Reclassified In US As Combo Products Get Regulatory Leeway
US FDA gives 12 month grace period for ophthalmic products once regulated as drugs to comply with requirements for combination products and temporarily exempts lower-risk constituents. Guidance specifies changes agency is making in response to Genus Medical v. FDA decision.
You may also be interested in...
The OCP presented its priorities for 2023 and beyond at the RAPS/AFDO Combination Products Summit on 8 November.
Sponsors are receiving information requests and complete response letters as a result of the agency’s transition plan, which was made in response to the Genus v. FDA ruling. The decision's aftershocks could reshape the landscape for a number of products, attorney says.
After losing the recent Genus Medical Technologies court case, the US FDA will begin transitioning certain imaging agent drugs to devices.